TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that Dror Harats, M.D., chief executive officer of VBL, is scheduled to present at the Fifth Annual JMP Securities Conference on Monday, September 27, 2010 at 4:30 p.m. EDT at the New York Palace Hotel.
